Groundbreaking in vivo work utilizing a rapidly progressing TDP-43 ALS mouse model showed that a single administration of ATXN2-ASO at birth resulted in sustained and significant reductions in ATXN2 mRNA levels, prolonged survival, and improved motor function. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.